ANI Pharmaceuticals, Inc. delivered robust 2025 results and issued bullish 2026 guidance. Learn more about ANIP stock here.
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or ...
As such, the results demonstrate that our oral gel platform enhances the delivery of lipophilic cannabinoid molecules and delivers more efficient uptake in the body. These results create a clear ...
Zacks.com on MSN
Will ANIP's Rare Disease Franchise Maintain Momentum in 2026?
ANIP's rare disease push, led by Cortrophin Gel, drove 70% sales growth in the first nine months of 2025, lifting revenue outlook.
The latest update is out from ANI Pharmaceuticals ( (ANIP) ).
There could be new hope in the fight against gum disease. Scientists have developed a toothpaste that targets only the ...
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 ...
6don MSN
The best pens for journaling, note-taking, drawing and more, approved by authors and editors
Get expert recommendations on the best pens to use from writers and authors. Shop pens from BIC, PaperMate, Sharpie and more ...
It is a condition that blights the lives of nearly 10 million Britons. Yet treatment options for osteoarthritisare limited.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback